“It’s quite an exceptional company with a medical advisory board of the who’s who of the cardiovascular space,” Pachacz says.
He says AVR has had some exceptionally good results in an early feasibility study with plans for a pivotal study involving around 200 patients.
“There’s two main competitors – Edwards Lifesciences and Medtronic,” he says.“So this company will probably get acquired at some point by one of those two companies, I would’ve thought” ———————————————
That planned pivotal study patient number of (only) 200 is new to me, much smaller than 1000+ patients I have seen mentioned elsewhere on this forum. Wonder if that would lead to an early 2025 FDA approval perhaps.
AVR Price at posting:
$20.05 Sentiment: Buy Disclosure: Held
(20min delay)